At Saarmetrics, we specialize in comprehensive pharmacometric services that enhance your Model-Informed Drug Discovery and Development (MID3) implementation from initial discovery through to final approval. Our tailored approaches integrate advanced techniques with thorough understanding of regulatory environments, ensuring optimal decision-making and strategic development.
At Saarmetrics, our mission is to enable pharmaceutical advancements by transforming complex data into actionable insights. We dedicate ourselves to understanding and meeting the unique needs of each client, delivering precise, customized pharmacometric analyses and decision support.
We offer a comprehensive suite of pharmacometric services, delivering solutions that enhance Model-Informed Drug Discovery and Development (MID3) strategies. Our expertise encompasses a variety of techniques, including population approaches (PopPK/PD), physiologically-based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology (QSP) modeling, and model-based meta-analysis (MBMA).
In the domain of regulatory and strategic consulting, we present comprehensive solutions for analysis and design such as drug-drug interaction (DDI) studies, pediatric scaling, and pediatric investigation plans (PIP) support, along with strategic regulatory advice and the design of efficient clinical trials. Our additional services extend to exploratory data analysis, non-compartmental analysis (NCA), implementation of interactive Shiny applications, pharmacometric training programs, and scientific manuscript writing.
Founded in 2019 as an academic spin-off from Saarland University, Saarmetrics combines academic insight with practical industry applications in pharmacometrics. Our team, experts in pharmacometrics and drug development, is committed to delivering precise, customized support throughout the drug development process.
We are recognized for our leadership in pharmacometrics consulting, measured by the quality and impact of our services. We continually refine our methodologies and technologies to meet the ever-evolving challenges of drug development. Having rapidly become a trusted consulting partner, we serve a spectrum from innovative biotech startups to leading pharmaceutical companies.
Saarmetrics is driven by a team with a collective experience of up to 25 years in pharmacometrics and global drug development. Our experts have extensive history in engaging with major regulatory authorities like the FDA, EMA, and PMDA, shaping drug development strategies through pivotal regulatory discussions and assessments.
We claim a track record of strategic development achievements, having crafted and implemented comprehensive pre-clinical and clinical plans that incorporate advanced biomarker development, leading to numerous successful drug approvals. Our clinical trial experience is extensive and varied, covering all phases of development.
Our team has contributed significantly to the body of knowledge in pharmacometrics, with over 200 scientific publications in esteemed peer-reviewed journals. This academic excellence feeds our innovative approach to advancing drug development.
Ready to explore how Saarmetrics can support your drug development journey? We invite you to reach out and discuss your pharmacometric needs with our team. Whether you are looking for strategic advice, detailed pharmacometric modeling, or comprehensive regulatory support, we are here to provide the expertise you need.
Saarmetrics GmbH
Starterzentrum 1
Universität des Saarlandes
66123 Saarbrücken
Germany
